Introduction. Levodopa is the gold-standard for treatment of Parkinson’s disease (PD) related motor symptoms. In this study, we used pseudo-continuous arterial spin labeling (pCASL) to quantify changes in cerebral blood flow (CBF) after acute oral administration of levodopa in PD patients.Materials and Methods. Thirteen patients (3 females, age 66.2 ± 8.7 years) with moderately advanced PD (Hoehn and Yahr stage >2 (median 2.5), disease duration >3 years) were scanned on a 3T Siemens MR scanner before and after oral levodopa administration. Statistical parametric mapping was used to detect drug-induced changes in CBF and its correlation to clinical severity scales. Images were normalized and flipped in order to examine effects on the more af...
Levodopa treatment in patients with Parkinson's disease (PD) is known to cause elevation in serum ho...
Dissociation of vasomotor and metabolic responses to levodopa has been observed in human subjects wi...
International audiencePatients with advanced Parkinson's disease (PD) develop disabling axial sympto...
Levodopa (l-dopa) has been at the forefront of antiparkinsonian therapy for a half century. Recent a...
The aim of this work was to study cerebral vasoreactivity to hypercapnia in Parkinson's disease (PD)...
Parkinson’s disease (PD) is a neurodegenerative illness often characterized by asymmetrical symptoms...
International audienceThe aim of this work was to study cerebral vasoreactivity to hypercapnia in Pa...
© 2017 The Author(s). Chronic levodopa treatment leads to the appearance of dyskinesia in the majori...
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is mainly char...
Idiopathic Parkinson's disease (IPD) is the second most common neurodegenerative disease, yet effect...
Idiopathic Parkinson's disease (IPD) is the second most common neurodegenerative disease, yet effect...
Levodopa treatment in patients with Parkinson's disease (PD) is known to cause elevation in serum ho...
Dissociation of vasomotor and metabolic responses to levodopa has been observed in human subjects wi...
International audiencePatients with advanced Parkinson's disease (PD) develop disabling axial sympto...
Levodopa (l-dopa) has been at the forefront of antiparkinsonian therapy for a half century. Recent a...
The aim of this work was to study cerebral vasoreactivity to hypercapnia in Parkinson's disease (PD)...
Parkinson’s disease (PD) is a neurodegenerative illness often characterized by asymmetrical symptoms...
International audienceThe aim of this work was to study cerebral vasoreactivity to hypercapnia in Pa...
© 2017 The Author(s). Chronic levodopa treatment leads to the appearance of dyskinesia in the majori...
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is mainly char...
Idiopathic Parkinson's disease (IPD) is the second most common neurodegenerative disease, yet effect...
Idiopathic Parkinson's disease (IPD) is the second most common neurodegenerative disease, yet effect...
Levodopa treatment in patients with Parkinson's disease (PD) is known to cause elevation in serum ho...
Dissociation of vasomotor and metabolic responses to levodopa has been observed in human subjects wi...
International audiencePatients with advanced Parkinson's disease (PD) develop disabling axial sympto...